SML2257
IBR2
≥98% (HPLC)
동의어(들):
(1R)-1,2-Dihydro-1-(1H-indol-3-yl)-2-[(phenylmethyl)sulfonyl]isoquinoline, (R)-2-(benzylsulfonyl)-1-(1H-indol-3-yl)-1,2-dihydroisoquinoline, Isoquinoline, 1,2-dihydro-1-(1H-indol-3-yl)-2-[(phenylmethyl)sulfonyl]-, (1R)-
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
실험식(Hill 표기법):
C24H20N2O2S
CAS Number:
Molecular Weight:
400.49
UNSPSC 코드:
12352200
NACRES:
NA.77
추천 제품
분석
≥98% (HPLC)
양식
powder
색상
white to beige
solubility
DMSO: 2 mg/mL, clear
저장 온도
2-8°C
SMILES string
O=S(N1[C@@H](C2=CNC3=C2C=CC=C3)C4=CC=CC=C4C=C1)(CC5=CC=CC=C5)=O
InChI key
YCOHEPDJLXZVBZ-XMMPIXPASA-N
생화학적/생리학적 작용
IBR2 is a cell penetrant, potent and specific RAD51 inhibitor that inhibits RAD51-mediated DNA double-strand break repair and enhances cytotoxicity of multiple anticancer agents with disparate biochemical targets including the Bcr-Abl inhibitor imatinib and multiple kinase inhibitor regorafenib. IBR2 disrupts RAD51 multimerization, accelerates proteasome-mediated RAD51 protein degradation, reduces ionizing radiation-induced RAD51 foci formation, inhibits cancer cell growth and induces apoptosis.
cell penetrant, potent and specific RAD51 inhibitor
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
Jiewen Zhu et al.
European journal of medicinal chemistry, 96, 196-208 (2015-04-16)
RAD51 recombinase plays a critical role for cancer cell proliferation and survival. Targeting RAD51 is therefore an attractive strategy for treating difficult-to-treat cancers, e.g. triple negative breast cancers which are often resistant to existing therapeutics. To this end, we have
A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.
Jiewen Zhu et al.
EMBO molecular medicine, 5(3), 353-365 (2013-01-24)
RAD51 recombinase activity plays a critical role for cancer cell proliferation and survival, and often contributes to drug-resistance. Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found in a panel of cancers, including breast cancer and
Peter J Ferguson et al.
The Journal of pharmacology and experimental therapeutics, 364(1), 46-54 (2017-10-25)
Although cancer cell genetic instability contributes to characteristics that mediate tumorigenicity, it also contributes to the tumor-selective toxicity of some chemotherapy drugs. This synthetic lethality can be enhanced by inhibitors of DNA repair. To exploit this potential Achilles heel, we
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.